CN110105453A - 运铁蛋白-肿瘤抑素融合蛋白质及其生成和使用方法 - Google Patents

运铁蛋白-肿瘤抑素融合蛋白质及其生成和使用方法 Download PDF

Info

Publication number
CN110105453A
CN110105453A CN201910156923.9A CN201910156923A CN110105453A CN 110105453 A CN110105453 A CN 110105453A CN 201910156923 A CN201910156923 A CN 201910156923A CN 110105453 A CN110105453 A CN 110105453A
Authority
CN
China
Prior art keywords
transferrin
tumorstatin
protein
cells
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910156923.9A
Other languages
English (en)
Chinese (zh)
Inventor
U·B·科姆佩拉
R·I·沙因曼
P·泰亚吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado System
Original Assignee
University of Colorado System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado System filed Critical University of Colorado System
Publication of CN110105453A publication Critical patent/CN110105453A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201910156923.9A 2011-08-17 2012-08-15 运铁蛋白-肿瘤抑素融合蛋白质及其生成和使用方法 Pending CN110105453A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161524508P 2011-08-17 2011-08-17
US61/524,508 2011-08-17
CN201280051256.4A CN103998470A (zh) 2011-08-17 2012-08-15 运铁蛋白-肿瘤抑素融合蛋白质及其生成和使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280051256.4A Division CN103998470A (zh) 2011-08-17 2012-08-15 运铁蛋白-肿瘤抑素融合蛋白质及其生成和使用方法

Publications (1)

Publication Number Publication Date
CN110105453A true CN110105453A (zh) 2019-08-09

Family

ID=47715692

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910156923.9A Pending CN110105453A (zh) 2011-08-17 2012-08-15 运铁蛋白-肿瘤抑素融合蛋白质及其生成和使用方法
CN201280051256.4A Pending CN103998470A (zh) 2011-08-17 2012-08-15 运铁蛋白-肿瘤抑素融合蛋白质及其生成和使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280051256.4A Pending CN103998470A (zh) 2011-08-17 2012-08-15 运铁蛋白-肿瘤抑素融合蛋白质及其生成和使用方法

Country Status (15)

Country Link
US (1) US9290562B2 (enExample)
EP (1) EP2744831B1 (enExample)
JP (1) JP6073888B2 (enExample)
CN (2) CN110105453A (enExample)
AU (1) AU2012296588B2 (enExample)
BR (1) BR112014008680A2 (enExample)
CA (1) CA2849015C (enExample)
DK (1) DK2744831T3 (enExample)
ES (1) ES2659161T3 (enExample)
NO (1) NO2820418T3 (enExample)
PL (1) PL2744831T3 (enExample)
PT (1) PT2744831T (enExample)
SI (1) SI2744831T1 (enExample)
TR (1) TR201802686T4 (enExample)
WO (1) WO2013025846A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014180288A1 (zh) * 2013-05-06 2014-11-13 中国药科大学 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用
JP2016522249A (ja) * 2013-06-20 2016-07-28 ノバルティス アーゲー 脈絡膜血管新生の治療におけるｖｅｇｆアンタゴニストの使用
US11058750B2 (en) * 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
KR101818151B1 (ko) 2016-03-25 2018-01-16 한국과학기술원 트렌스페린을 포함하는 허혈성망막병증 예방 및 치료용 조성물
CN109053899B (zh) * 2017-12-22 2021-11-16 湖南远泰生物技术有限公司 一种含人转铁蛋白抗原表位序列的嵌合体抗原受体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060172941A1 (en) * 2004-10-14 2006-08-03 Luca Rastelli Anti-angiogenic peptides and methods of use thereof
CN101070349A (zh) * 2007-05-22 2007-11-14 山西康宝生物制品股份有限公司 具有选择性杀伤肿瘤新生血管内皮细胞作用的融合蛋白与应用
CN101092452A (zh) * 2007-05-23 2007-12-26 哈尔滨医科大学 肿瘤抑素抗血管生成小分子多肽、融合蛋白及两者制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US20050192242A1 (en) 1995-10-11 2005-09-01 Neal Zane C. Therapeutic fusion protein transgenes
AU753249B2 (en) * 1998-06-17 2002-10-10 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and methods of use thereof
JP2003517847A (ja) 1999-12-23 2003-06-03 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド トランスフェリンポリヌクレオチド、ポリペプチド、および抗体
US8129504B2 (en) * 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
CA2457520A1 (en) 2001-08-30 2003-03-13 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
NZ534492A (en) * 2002-02-07 2009-10-30 Novozymes Delta Ltd Albumin-fused kunitz domain peptides
EP1670428A4 (en) 2003-10-10 2008-03-12 Univ Southern California HYBRID PROTEINS G-CSF-TRANSFERRIN
EP1722762A2 (en) * 2004-03-02 2006-11-22 Massachusetts Institute of Technology Nanocell drug delivery system
WO2006049983A2 (en) 2004-10-27 2006-05-11 Biorexis Pharmaceutical Corporation Peptide yy modified transferrin fusion proteins
EP1881849A2 (en) * 2005-04-29 2008-01-30 Research Development Foundation Vascular targeting of ocular neovascularization
EP1988915B1 (en) 2006-02-03 2012-03-28 Crc For Asthma And Airways Ltd Tumstatin for the treatment of conditions associated with airway tissue remodeling
US7943733B2 (en) * 2007-12-20 2011-05-17 University Of Southern California Spacers to increase the expression of recombinant fusion proteins
JP6101638B2 (ja) 2011-03-03 2017-03-22 ザイムワークス，インコーポレイテッド 多価ヘテロマルチマー足場設計及び構築物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060172941A1 (en) * 2004-10-14 2006-08-03 Luca Rastelli Anti-angiogenic peptides and methods of use thereof
CN101070349A (zh) * 2007-05-22 2007-11-14 山西康宝生物制品股份有限公司 具有选择性杀伤肿瘤新生血管内皮细胞作用的融合蛋白与应用
CN101092452A (zh) * 2007-05-23 2007-12-26 哈尔滨医科大学 肿瘤抑素抗血管生成小分子多肽、融合蛋白及两者制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KRYSTEN M FARJO等: "The potential of nanomedicine therapies to treat neovascular Disease in the retina", 《JOURNAL OF ANGIOGENESIS RESEARCH》 *

Also Published As

Publication number Publication date
EP2744831A2 (en) 2014-06-25
AU2012296588B2 (en) 2017-07-27
JP6073888B2 (ja) 2017-02-01
DK2744831T3 (en) 2018-03-05
WO2013025846A3 (en) 2013-05-02
BR112014008680A2 (pt) 2017-06-13
JP2014526890A (ja) 2014-10-09
AU2012296588A1 (en) 2014-04-03
PT2744831T (pt) 2018-03-05
PL2744831T3 (pl) 2018-05-30
EP2744831B1 (en) 2017-12-06
US9290562B2 (en) 2016-03-22
CA2849015A1 (en) 2013-02-21
TR201802686T4 (tr) 2018-03-21
EP2744831A4 (en) 2015-03-11
CA2849015C (en) 2017-08-08
SI2744831T1 (en) 2018-04-30
WO2013025846A2 (en) 2013-02-21
US20140179612A1 (en) 2014-06-26
CN103998470A (zh) 2014-08-20
NO2820418T3 (enExample) 2018-05-05
ES2659161T3 (es) 2018-03-14

Similar Documents

Publication Publication Date Title
CN110036024B (zh) 肌肉性能改善化合物
Amaral et al. Effects of human recombinant PEDF protein and PEDF-derived peptide 34-mer on choroidal neovascularization
CN106255699B (zh) 细胞穿透肽和使用其输送生物活性物质的方法
DK2744831T3 (en) TRANSFERRIN-TUMSTATIN-FUSION PROTEIN AND PROCEDURES FOR PREPARING AND USING THE SAME
Johnen et al. Antiangiogenic and Neurogenic Activities of Sleeping Beauty‐Mediated PEDF‐Transfected RPE Cells In Vitro and In Vivo
CN103930439A (zh) 基因工程生长因子变异体
Darche et al. Antagonist of nucleolin, N6L, inhibits neovascularization in mouse models of retinopathies
US9469679B2 (en) Neurturin molecules
JP6440107B2 (ja) 細胞シートの製造方法、組成物、細胞培養補助剤、及び細胞培養方法
Talreja et al. G-quartet oligonucleotide mediated delivery of functional X-linked inhibitor of apoptosis protein into retinal cells following intravitreal injection
JP7560185B2 (ja) 補体経路阻害剤及び血管新生阻害剤を含む融合タンパク質並びにその使用
EP2774935B1 (en) Improved neurturin molecules
JP2024543158A (ja) 多重特異性リガンド結合分子及びその用途
US8445432B2 (en) Neurturin molecules
Piroozmand et al. MiRGD peptideticle targeted delivery of hinge-truncated soluble VEGF receptor 1 fusion protein to the retinal pigment epithelium cell line and newborn mice retina
Chatenet et al. PACAP-derived carriers: mechanisms and applications
CN120476152A (zh) C5/vegf双特异性结合分子
EP3096769A1 (en) Therapeutic use of vegfr-3 ligands
CN119522235A (zh) 用于选择性淋巴管刺激的vegf-c突变蛋白
Kumar-singh Platform for Rapid Delivery of Biologics and Drugs to Ocular Cells and Tissues Following Combat Associated Trauma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190809